RVL Pharmaceuticals, Inc, the maker of Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business.

RVL's Board of Managers has appointed Lori Deo as Chief Executive Officer. Deo was Executive Chairwoman of the Board for RVL prior to this appointment (the Chairperson role will now be held by affiliates of RVL's majority shareholder, Athyrium Capital Management, LP). Deo is a dynamic and experienced healthcare executive with general management experience at world class companies including Johnson & Johnson and Pfizer. She has a proven track record of building and scaling brands and businesses across the healthcare and beauty landscape. As CEO, she will lead RVL's strategy to expand market penetration and drive revenue acceleration, working in close partnership with the healthcare professional community.

The company has also appointed Amy Shah as Chief Growth Officer. Shah is a transformational leader with a distinguished record of architecting growth strategies and inspiring high-performing teams across the pharmaceutical, OTC, and beauty landscape. During her 20-year career at Johnson & Johnson, she led enterprise reinvention, from pioneering integrated consumer experience models to advancing technology-driven engagement strategies that reshaped trajectories for leading brands. In this expanded role, Shah will be responsible for an integrated commercial organization across sales, marketing, innovation, and pipeline development.

"RVL is entering a pivotal next phase of growth," said Lori Deo, Chief Executive Officer. "These leadership appointments strengthen our ability to scale, deepen engagement with consumers and healthcare providers, and fully capitalize on the category-defining potential of Upneeq®, with an estimated $2.5B Total Addressable Market (TAM). We are committed to investing with intention to unlock TAM, build and scale a new category, and accelerate brand and platform momentum."

RVL Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. Its first approved product, Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, provides the foundation of its commitment to improve patients' lives. Upneeq is available through the UP+ program, which allows you to dispense Upneeq directly to your appropriate adult patients. View important safety information and full prescribing information at upneeq.com.